Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C4528257
Disease: Corpuscular Hemoglobin Concentration Mean
Corpuscular Hemoglobin Concentration Mean 		0.100 GeneticVariation phenotype GWASDB Seventy-five genetic loci influencing the human red blood cell. 23222517 2012
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.020 Biomarker group BEFREE Screens of the NCI-60 human tumor cell lines reveal that arsenoplatin-1 (AP-1), [Pt(μ-NHC(CH<sub>3</sub>)O)<sub>2</sub>ClAs(OH)<sub>2</sub>], the first representative of this novel class of anticancer agents, displays a superior activity profile relative to the parent drugs As<sub>2</sub>O<sub>3</sub> or cisplatin in a majority of cancer cell lines tested. 30943017 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.020 Biomarker group BEFREE Mouse and human cells overexpressing HMGN4 show increased tumorigenicity as measured by colony formation, by tumor generation in nude mice, and by the formation of preneoplastic lesions in the thyroid of transgenic mice. 28186538 2017
CUI: C0011175
Disease: Dehydration
Dehydration 		0.010 Biomarker phenotype BEFREE NHC-catalyzed silylative dehydration of primary amides to nitriles at room temperature. 31830152 2020
CUI: C0206752
Disease: Alphavirus Infections
Alphavirus Infections 		0.010 Biomarker group BEFREE To address the need for a therapeutic agent for the treatment of Alphavirus infections, we identified and pursued preclinical characterization of a ribonucleoside analog EIDD-1931 (β-D-N<sup>4</sup>-hydroxycytidine, NHC), which has shown broad activity against alphaviruses in vitro and has a very high genetic barrier for development of resistance. 31494195 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.010 Biomarker disease BEFREE Patients with high levels of YWHAZ, ENAH, and HMGN4 tended to have high-grade tumors and shorter overall survival, suggesting that these genes could be promising candidate biomarkers for disease and poor prognosis in patients with HCC. 30272824 2019
CUI: C0268059
Disease: Neonatal hemochromatosis
Neonatal hemochromatosis 		0.010 GeneticVariation disease BEFREE [Ru<sub>3</sub>(6-NHC)(CO)<sub>10</sub>]: synthesis, characterisation and reactivity of rare 46-electron tri-ruthenium clusters. 29505057 2018
CUI: C0007115
Disease: Malignant neoplasm of thyroid
Malignant neoplasm of thyroid 		0.010 Biomarker disease BEFREE Our study identifies a novel epigenetic factor that potentiates thyroid oncogenesis and raises the possibility that HMGN4 may serve as an additional diagnostic marker, or therapeutic target in certain thyroid cancers. 28186538 2017
CUI: C0018834
Disease: Heartburn
Heartburn 		0.010 Biomarker phenotype BEFREE Such dissimilar reactivity between the unsaturated and saturated NHC ligands is predominantly ascribed to the increased acidity of azolium salts along with the π-donor strength of the C<sub>carbene</sub> in L2 and L3-Zr moieties. 28604887 2017
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm 		0.010 AlteredExpression disease BEFREE Bioinformatics analyses reveal increased HMGN4 expression in thyroid cancer. 28186538 2017
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma 		0.010 Biomarker disease BEFREE Our study identifies a novel epigenetic factor that potentiates thyroid oncogenesis and raises the possibility that HMGN4 may serve as an additional diagnostic marker, or therapeutic target in certain thyroid cancers. 28186538 2017
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.010 AlteredExpression phenotype BEFREE Our study identifies a novel epigenetic factor that potentiates thyroid oncogenesis and raises the possibility that HMGN4 may serve as an additional diagnostic marker, or therapeutic target in certain thyroid cancers. 28186538 2017